Floatz logo

DEXAMETHASONE

Blinatumomab

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Blinatumomab cohort.

Asset / SponsorPhaseRating
Blinatumomab
M.D. Anderson Cancer Center
Phase 2B
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 2CCC
Inotuzumab Ozogamicin
The First Affiliated Hospital of Soochow University
Phase 2CCC
METHOTREXATE
M.D. Anderson Cancer Center
Phase 2CCC
Olverembatinib
M.D. Anderson Cancer Center
Phase 2CCC
PREDNISONE TABLETS
M.D. Anderson Cancer Center
Phase 2CCC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2CCC
Revumenib
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →